Protein Interact. Track Settings
Human Interacting Proteins from Gordon et al. (* = druggable)   (All Genes and Gene Predictions tracks)

Display mode:      Duplicate track

Show only items with score at or above:   (range: 0 to 1000)

Shade of lowest-scoring items:

Display data as a density graph:

Data schema/format description and download
Assembly: SARS-CoV-2 Jan. 2020 (NC_045512.2)
Data last updated at UCSC: 2020-04-29 09:02:42


This track shows data from Gordon et al, 2020 "A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing".

The authors cloned, tagged, and expressed 26 of the mature proteins expressed by SARS-CoV-2 in 293 human cells and used affinity purification mass spectrometry (AP-MS) to identify human proteins that interact with viral proteins.

332 high confidence interactions are reported betwen human and viral proteins.

Display Conventions and Configuration

On the viral genome the coordinates of the viral protein are marked and labeled with the name of the human interactor.

The bed file also includes the MIST score * 1000. A MIST score of 1 is a highly reproducible and specific interaction, scores are multipled by 1000 for display purposes.

The set of interactions displayed here includes only the 332 "high confidence" interactions that met criteria for significance (using a MIST cutoff >= 0.7 as well as "a SAINTexpress BFDR <= 0.05 and an average spectral count >= 2.").


The tab delimited version of supplementary table 2 was downloaded from biorxiv. This table lists the viral protein that served as the "bait" and Uniprot identifiers of human proteins that were captured as "prey".

A version of the "UniProt Mature Protein Products (Polypeptide Chains)" track was then manually modified to rename ORFs to match paper nomenclature as indicated by Figure 1.

The table was then joined and MIST scores multipled by 1000 to produce a track reporting interactions.


Gordon et al, "A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing", Biorxiv 2020